Zhejiang Starry Pharmaceutical is an API manufacturer based in China. It holds 4 active US drug master files and 7 valid CEPs across a filed portfolio of 6 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 6 September 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Xianju, China | Not on file |
| China, China | 3007027206 |
| Molecule | Regulators | Docs |
|---|---|---|
| Iopamidol | EDQM, US FDA | 4 |
| Iodixanol | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Iohexol | EDQM, US FDA | 3 |
| Iopromide | EDQM | 1 |
| Levofloxacin | EDQM | 1 |
| Lohexol | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Zhejiang Starry Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free